Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Jeremy Hayden sold 9,731 shares of the stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $3.27, for a total transaction of $31,820.37. Following the completion of the sale, the insider directly owned 256,590 shares in the company, valued at approximately $839,049.30. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Sight Sciences Price Performance
NASDAQ SGHT traded down $0.02 on Friday, hitting $3.29. The stock had a trading volume of 145,273 shares, compared to its average volume of 185,355. The firm has a 50-day moving average of $3.75 and a 200-day moving average of $3.47. The company has a debt-to-equity ratio of 0.57, a quick ratio of 9.49 and a current ratio of 10.01. Sight Sciences, Inc. has a 52-week low of $2.03 and a 52-week high of $6.29. The company has a market capitalization of $172.29 million, a price-to-earnings ratio of -3.43 and a beta of 2.42.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. Sight Sciences had a negative return on equity of 59.38% and a negative net margin of 64.23%.The company had revenue of $19.56 million during the quarter, compared to analyst estimates of $18.18 million. Sight Sciences has set its FY 2025 guidance at EPS. Equities analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have commented on SGHT shares. Wall Street Zen raised shares of Sight Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. Lake Street Capital upgraded shares of Sight Sciences from a "hold" rating to a "buy" rating and upped their target price for the stock from $3.00 to $5.00 in a research report on Friday, August 8th. Needham & Company LLC restated a "hold" rating on shares of Sight Sciences in a research report on Thursday, August 28th. Weiss Ratings reissued a "sell (d-)" rating on shares of Sight Sciences in a report on Saturday, September 27th. Finally, Citigroup upped their target price on Sight Sciences from $3.60 to $4.50 and gave the stock a "neutral" rating in a research note on Thursday, August 21st. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $4.42.
Get Our Latest Stock Analysis on SGHT
Institutional Investors Weigh In On Sight Sciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its position in shares of Sight Sciences by 32.7% in the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company's stock valued at $48,000 after acquiring an additional 2,875 shares during the period. Jane Street Group LLC purchased a new position in Sight Sciences during the 2nd quarter valued at about $148,000. B Group Inc. raised its position in Sight Sciences by 11.6% during the 2nd quarter. B Group Inc. now owns 930,000 shares of the company's stock valued at $3,841,000 after purchasing an additional 96,400 shares during the last quarter. Panagora Asset Management Inc. bought a new position in Sight Sciences during the 2nd quarter valued at approximately $132,000. Finally, XTX Topco Ltd purchased a new stake in Sight Sciences in the 2nd quarter worth approximately $67,000. 55.51% of the stock is currently owned by institutional investors.
About Sight Sciences
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sight Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.
While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
